ImpediMed Announces Q4 FY26 Results: $3.6M Revenue, 95% US Reimbursement Coverage, and $15.3M Capital Raise

ImpediMed’s SOZO Platform: Leading FDA-Cleared Body Composition Technology

ImpediMed Limited’s SOZO® Digital Health Platform is a cloud-based system delivering advanced body composition and fluid measurement outputs. The SOZO technology holds FDA clearance, TGA clearance, and CE Mark certification, securing regulatory approvals in major global markets. It is uniquely positioned as the only bioelectrical impedance spectroscopy (BIS) device cleared for use in patients with implantable cardiac devices and those with health conditions, distinguishing it clinically.

The company has strategically obtained multiple FDA clearances for SOZO Pro and SOZO across three core indications: lymphoedema, body composition measurement (BodyComp), and heart failure monitoring. This multi-indication framework enables ImpediMed to leverage its platform across expanding healthcare sectors, enhancing operational efficiency while broadening clinical applications. The extensive regulatory approvals position ImpediMed as a comprehensive digital health measurement provider.

US Reimbursement Coverage Expands to 331 Million Lives

ImpediMed achieved 95.0% national reimbursement coverage in the US, representing 331 million covered lives. During Q4 FY26, the number of states with over 80% coverage rose from 47 to 49, states exceeding 90% coverage increased from 45 to 47, and those above 95% coverage grew from 37 to 38, reflecting steady reimbursement penetration growth nationwide.

This expanded coverage addresses a key adoption barrier in the US healthcare market, facilitating increased device sales and utilization across healthcare systems. The reimbursement progress supports broader clinical deployment, particularly in cancer survivorship and heart failure monitoring, where reimbursement has historically limited uptake. Near-universal coverage provides a foundational advantage for ImpediMed’s market expansion.

Cancer Survivorship Segment Driving Clinical Adoption

The cancer survivorship market presents a major growth opportunity, with an estimated 18 million cancer survivors in the US, increasing by over 1 million annually. ImpediMed highlights the growing multidisciplinary focus on survivorship programs that enhance patient quality of life and reduce recurrence risk. Up to 60% of survivors report fear of recurrence, fueling demand for comprehensive survivorship care including wellness and exercise oncology.

ImpediMed’s Lymphoedema+ strategy leverages body composition data to provide objective clinical measurements beyond patient-reported outcomes, aiding treatment assessment and long-term survivorship planning. The company has deepened engagement with key opinion leaders and benefits from NCCN and NAPBC guidelines promoting lymphoedema surveillance and survivorship program use. There is significant potential to expand integrated delivery network and oncology partnerships in this segment.

Heart Failure Monitoring Market and SOZO Pro’s Unique Position

The US outpatient heart failure monitoring market is estimated at $600 million. With approximately 6.7 million heart failure patients and 1 million new diagnoses annually, the clinical and economic burden, especially hospital readmissions, drives demand for continuous monitoring solutions.

SOZO Pro stands as the only FDA-cleared BIS device for heart failure patient monitoring, establishing a unique market position. Regulatory clearances for multiple indications, including heart failure, underpin clinical expansion. Hospital readmission prevention and fluid status monitoring are key clinical outcomes addressed by SOZO Pro. The company’s 27 integrated delivery network master service agreements provide access to over 1,400 hospital opportunities, enabling scale in heart failure monitoring programs.

Installed Base of 642 Devices in Leading US Healthcare Systems

ImpediMed’s installed base includes 642 SOZO devices across prominent US healthcare customers, including 18 of the top 25 hospitals. These relationships create referral pathways within hospital networks, amplifying adoption potential. The 27 master service agreements with integrated delivery networks offer coordinated access across multiple hospitals.

This extensive installed base and customer network provide a platform for accelerated growth. Completed IT assessments and contracts facilitate rapid approvals for new applications within existing institutions. The 1,400+ hospital opportunities embedded in these agreements represent a significant addressable market for expanding SOZO utilization across clinical departments and patient populations.

Q4 FY26 Device Sales: 40 Units with 6.7% Price Increase

During Q4 FY26, ImpediMed sold 40 SOZO devices globally, including 36 in the US and 4 internationally. While year-over-year growth rates were not disclosed, these unit sales offer a tangible quarterly performance metric. Sales activity focused on the US reflects strategic prioritization of this mature market with expanded reimbursement and healthcare system adoption.

The company achieved a 6.7% average price increase on renewed US contracts, indicating strong pricing power and customer willingness to pay higher rates. This may reflect enhanced clinical value perception or improved negotiation leverage as clinical and economic benefits accumulate. No guidance was provided on device sales for Q1 FY27 or beyond.

Total Contract Value of $5.4M and Annual Recurring Revenue of $14.4M

ImpediMed reported a total contract value of $5.4 million for Q4 FY26, representing the full value of contracts signed during the quarter. This differs from quarterly revenue of $3.6 million due to revenue recognition timing. Annual recurring revenue stood at $14.4 million at quarter-end, stable in constant currency compared to $14.6 million in Q3 FY26, indicating a steady subscription and recurring revenue base despite fluctuations in device sales.

The company’s revenue model blends device sales with recurring software or subscription services, consistent with its digital health platform approach. The announcement did not disclose revenue breakdowns or the proportion of ARR expected to convert to revenue in future periods.

$15.3M Capital Raise and Strong Cash Position

ImpediMed completed a $15.3 million capital raise in Q4 FY26, bolstering its financial position. A partial loan repayment of $5.0 million was made from these proceeds, reflecting debt management alongside growth investment. The company reported a quarterly operating cash outflow of $4.9 million.

Cash on hand was $15.3 million at quarter-end, sufficient to cover 3.1 quarters of operating cash flow at the current burn rate. Details on capital raise terms, including share price and investor composition, were not disclosed. While the cash runway supports operations into Q1 FY27, additional funding or profitability will be necessary to sustain longer-term operations. Managing cash flow while investing in product development and market expansion remains a key investor focus.

Emerging GLP-1 Weight Management Market Opportunity

ImpediMed identified the growing GLP-1-driven weight management market as a key opportunity, emphasizing the clinical need to measure and preserve muscle mass during weight loss interventions. The expanding use of GLP-1 receptor agonists for diabetes and weight loss creates a large patient population seeking body composition monitoring.

This segment is one of three primary markets targeted alongside cancer survivorship and heart failure. Although specific market size data was not provided, ImpediMed positions SOZO’s body composition capabilities as addressing an emerging clinical demand. Future revenue growth may be influenced by the company’s ability to capture share in this rapidly evolving space.

New Executive Leadership and Strategic Focus

The company update references new executive leadership guiding the SOZO Digital Health Platform strategy. While details on leadership changes were not disclosed, these transitions aim to enhance strategic direction and operational execution.

The timing of leadership changes, combined with the capital raise and focus on three defined market segments, indicates a strategic inflection point. The company emphasizes coordinated engagement across clinical, operational, financial, and executive stakeholders to drive adoption in complex healthcare environments. Investors should watch for forthcoming details on executive appointments and strategic priorities.

Forward-Looking Risks and Market Challenges

ImpediMed’s presentation includes forward-looking statements, cautioning that actual results may differ materially. Risks include challenges in expanding sales and market acceptance in the US and Australia, product commercialization, clinical trials, regulatory approvals, and intellectual property protection.

The company advises investors not to rely unduly on forward-looking statements and notes no obligation to update them except as required by law. Risks inherent to medical device and digital health sectors—such as regulatory hurdles, reimbursement uncertainties, clinical evidence generation, and competitive pressures—may impact commercial success. Prospective investors should carefully assess these risks and seek independent advice before investing.